Attached files
file | filename |
---|---|
EX-1.1 - EX-1.1 - IDENIX PHARMACEUTICALS INC | b89085exv1w1.htm |
EX-5.1 - EX-5.1 - IDENIX PHARMACEUTICALS INC | b89085exv5w1.htm |
8-K - FORM 8-K - IDENIX PHARMACEUTICALS INC | b89085e8vk.htm |
Exhibit 99.1
Idenix Pharmaceuticals Contacts:
Kelly Barry (617) 995-9033 (media)
Eric Hoffman (617) 224-4485 (investors)
Kelly Barry (617) 995-9033 (media)
Eric Hoffman (617) 224-4485 (investors)
Idenix Pharmaceuticals Prices Public Offering of Common Stock
CAMBRIDGE, Mass., November 16, 2011 Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a
biopharmaceutical company engaged in the discovery and development of drugs for the treatment of
human viral diseases, today announced the pricing of an underwritten registered public offering of
9,393,416 shares of its common stock at a public offering price of $6.50 per share. All of the
shares are being sold by Idenix. The offering is expected to close on November 21, 2011, subject to
customary closing conditions.
J.P. Morgan Securities LLC is acting as sole book-running manager and underwriter for the offering.
Idenix has granted the underwriter a 30-day option to purchase up to an additional 1,409,013
shares to cover over-allotments, if any.
The shares will be issued pursuant to a shelf registration statement on Form S-3 previously filed
with and declared effective by the Securities and Exchange Commission. Idenix will also file with
the Securities and Exchange Commission a prospectus supplement with respect to the offering.
This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any
securities of Idenix, nor shall there be any offer or sale of securities in any state or
jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus
supplement and accompanying prospectus may be obtained, when available, from J.P. Morgan Securities
LLC via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling
toll-free (866) 803-9204.
MTS Securities, LLC provided financial advisory services to Idenix.
About Idenix
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical
company engaged in the discovery and development of drugs for the treatment of human viral
diseases. Idenixs current focus is on the treatment of infections caused by the hepatitis C virus.